What exists. What is permitted. How long it takes.
Three different questions, and the second one is where regional programmes die. A dataset that cannot be analysed for your purpose, or cannot leave the country, or needs two sequential approvals, is not a dataset you can use, and finding that out in month four is expensive.
Nine markets. Eight health systems and one hospital network.
Select a market, either on the map or from the buttons beside it, to see what is there. Every market is also listed in full below, so nothing here depends on the map working.
Coastlines and borders are drawn from public geographic data on a Mercator projection. Markers indicate the markets we work in, not the location of any data holder.
Market footprint counts the resident population of the eight national and territorial health systems we work in. It excludes India, where we work through a cross-border oncology hospital network rather than a national health system. Data footprint counts only markets with a substantiated market-scale patient-level asset; it counts Japan at accessible-database scale rather than national population, and China at the size of the smallest region we work in rather than the average. Both figures are rounded down.
What each market is actually good for.
Market 1 of 9 Australia Deepest coverage, and our own analytics product
National scheme-level pharmaceutical and medical-services claims, hospital activity and hospital principal-diagnosis data are published openly, and are the foundation of Health Grid Platform, our subscription analytics product. Patient-level work runs through alliance partners alongside it, including national and state linked collections carrying up to 25 years of history.
Data types available
Speed: Days for scheme-level questions through Health Grid Platform. Four to six weeks for patient-level feasibility.
Market 2 of 9 China The deepest portfolio, and the hardest access architecture
There is no national clinical data repository in China. Access is negotiated regionally, per institution or through an aggregator, and governance rules differ by province. Our coverage spans four city-level databases from tier 1 through tier 3 facilities, a district cohort of 1.6 million residents with more than ten years of history, and an oncology genomic database of over 100,000 patients.
Data types available
Speed: Feasibility in weeks. Study timelines are governed by regional approval, not by analysis. China work is data-source only: no primary research and no interview-based work.
Market 3 of 9 Japan The largest accessible claims environment in the region
Hospital and insurance claims at tens of millions of patients, with laboratory values in several sources, plus electronic medical records linked to claims across ninety or more institutions. Japan is also the one market where direct access to source data can sometimes be arranged, on conditions set case by case by the alliance partner. It is discussed directly rather than advertised, and it is not a general offer.
Data types available
Speed: Feasibility in weeks, then access-dependent.
Market 4 of 9 South Korea Near-universal single-payer claims, plus a federated hospital network
Government claims cover 97 to 98 per cent of the population and are available through four access routes with different granularity, from open summary statistics through to full longitudinal raw claims. Alongside them sits a federated hospital electronic medical record network of more than fifty hospitals and sixty-nine million patients, where evidence is shared rather than data.
Data types available
Speed: Four to six weeks for feasibility where access is established.
Market 5 of 9 Taiwan Four national-scale assets, three of which link to each other
The strongest linkage story in the region. National claims covering 99.9 per cent of the population from 1995, a cancer registry covering more than 98 per cent of cancer patients and linkable to claims by patient identifier, a biobank of 267,000 participants with multi-omics data, and a multi-institution hospital EMR collection with a data lag under one month.
Data types available
Speed: Four to six weeks for feasibility where access is established.
Market 6 of 9 Singapore Concentrated, high quality and governance-heavy
A national electronic health record consolidating summary records across public and private providers, with all nine private hospitals contributing and roughly 70 per cent of the primary care sector. Genomic and clinical data sit unusually close together, which is what makes precision-medicine and biomarker questions answerable here rather than merely askable.
Data types available
Speed: Feasibility in weeks. Governance review is the determining factor.
Market 7 of 9 New Zealand Small in absolute numbers, exceptional in linkage
National claims, hospital admitted and non-admitted activity, laboratory data, the national cancer registry and the mortality collection can be joined at person level in ways that are impossible in most larger markets. That is what makes true patient-journey and survival questions answerable here.
Data types available
Speed: Four to six weeks for feasibility. Approval timelines are the long pole.
Market 8 of 9 Hong Kong Territory-wide longitudinal clinical records
A territory-wide electronic health record covering all public hospitals and clinics since 1993, in a single record architecture, reaching more than 90 per cent of inpatient and more than 80 per cent of outpatient services. Coding accuracy has been formally validated, with published positive predictive values from 85 to 100 per cent depending on the condition.
Data types available
Speed: Four to six weeks for a first feasibility read where access is established.
Market 9 of 9 India A cross-border oncology hospital network, not a health system
We reach India through a cross-border oncology hospital network rather than a national health system, and we count it separately from the eight national and territorial systems for exactly that reason. Near real-time de-identified patient profiles, with digitised genomic data, across a network spanning several markets.
Data types available
Speed: Feasibility in weeks, then network-dependent.
Depth here. Reach elsewhere, stated honestly.
Our proven depth is in these nine markets, that is where the alliance partners, the governance knowledge and the track record are. Where your question sits outside the region and a data partner exists, we will tell you plainly what we can and cannot do there, rather than quietly stretching a regional capability over a global map.
The test we apply is simple. If we cannot name the route to the data, the permission it needs and the person who has done it before, we are not the right supplier for that market, and saying so early is worth more to you than a proposal that discovers it in month four.
An alliance network, disclosed where it counts.
Nine markets are covered by a standing network of alliance partners, each one a long-standing relationship rather than a one-off purchase. The network is how the coverage exists at all, and it is maintained the way the partners require.
- The relationships are contractual, and mutual. Partners are named to you in the contract by role, and by name under NDA on request. That is the form they have agreed to, and honouring it is what keeps the access open for your programme.
- A standing network beats a market search. Because the relationships already exist, scoping starts at the question rather than at the introduction, which is where most regional timelines are lost.
- The right question is what the data can answer. Every deliverable states the data type, the grain, the coverage, the vintage and the limitations, which is what a reviewer, a regulator or a payer actually assesses.
In practice: you buy the network's reach and a single accountable counterparty in Australia. One contract, one currency, one set of standards, and a named local expert on every market in scope.
The network keeps growing. We add partners where a market, a data type or a therapy area is asked for often enough to justify a standing relationship. If you hold or govern health data in the region, we would like to hear from you.
Tell us the market and the question.
We will tell you whether the data can answer it, from which data type, and how long it will take.